Dapagliflozin Plus Calorie Restriction Increased Type 2 Diabetes Remission in Early Disease
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
SGLT2 Inhibitors
Evidence summaries for SGLT2 inhibitors across diabetes, heart failure, chronic kidney disease, cardiovascular outcomes, renal protection, and safety.
CONFIDENCE: Finerenone Plus Empagliflozin Reduced Albuminuria More Than Either Drug Alone
In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.
Fixed-Dose Versus Separate Enavogliflozin/Gemigliptin: A Phase 1 Pharmacokinetic and Safety Study
A Phase 1 crossover study in healthy Korean volunteers found the enavogliflozin/gemigliptin fixed-dose combination pharmacokinetically equivalent to the separate tablets, with food not altering enavogliflozin exposure. PICO summary and expert commentary.
Does Dapagliflozin Improve Heart Blood Flow Long-Term in Type 2 Diabetes?
The DAPAHEART follow-up finds 4 years of dapagliflozin improves coronary flow reserve and reduces epicardial fat in type 2 diabetes. PICO summary and expert commentary.
DAPA-CKD: Dapagliflozin Reduces Kidney Failure by 39% in Albuminuric CKD Regardless of Diabetes Status
DAPA-CKD demonstrated that dapagliflozin reduced the composite of a sustained 50% or greater eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% in patients with albuminuric CKD with or without type 2 diabetes, extending nephroprotective SGLT2 inhibition beyond diabetic nephropathy to a broad CKD population for the first time.
EMPEROR-Reduced: Empagliflozin Reduces Heart Failure Hospitalisation and Preserves Renal Function in HFrEF
EMPEROR-Reduced confirmed that empagliflozin reduces cardiovascular death or hospitalisation for heart failure by 25% in patients with HFrEF irrespective of diabetes status, while also demonstrating a 50% reduction in a renal composite outcome and a markedly slower rate of eGFR decline, adding critical confirmatory evidence for SGLT2 inhibitors as standard-of-care in HFrEF.
DAPA-HF: Dapagliflozin Reduces Worsening Heart Failure and Cardiovascular Death Regardless of Diabetes Status
The DAPA-HF trial demonstrated that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% in patients with heart failure and reduced ejection fraction, with consistent benefit observed in both those with and without type 2 diabetes, establishing SGLT2 inhibition as a core therapy for HFrEF independent of glycaemic status.
Can Sirtuins and miRNAs Predict Heart Recovery After Taking Empagliflozin?
A biomarker substudy finds empagliflozin modulates sirtuins and microRNAs after myocardial infarction, with a panel predicting recovery. PICO summary and expert commentary.
Can Empagliflozin Improve Nerve Function in Type 2 Diabetes?
A 20-week RCT finds empagliflozin improves nerve conduction velocity in diabetic neuropathy but not clinical exam scores, with glycaemic confounding. PICO summary and commentary.
CREDENCE: Canagliflozin Reduces Kidney Failure by 30% in Type 2 Diabetes and Albuminuric Nephropathy
The CREDENCE trial demonstrated that canagliflozin reduced the composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death by 30% in patients with type 2 diabetes and albuminuric chronic kidney disease, becoming the first dedicated renal outcomes trial to demonstrate that an SGLT2 inhibitor could substantially slow the progression of diabetic nephropathy.